M D Kramer
Overview
Explore the profile of M D Kramer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
2227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schaefer B, Wallich R, Schmolke K, FINK W, Bechtel M, Reinartz J, et al.
Exp Dermatol
. 2000 Feb;
9(1):58-64.
PMID: 10688376
Keratinocyte activation comprises changes in protein and gene expression pattern resulting in phenotypic and functional changes necessary for re-epithelialization such as the expression of urokinase-type plasminogen activator (uPA) and its...
12.
Foekens J, Peters H, Look M, Portengen H, Schmitt M, Kramer M, et al.
Cancer Res
. 2000 Feb;
60(3):636-43.
PMID: 10676647
The antigen levels of components of the urokinase-type plasminogen activator (uPA) system of plasminogen activation are correlated with prognosis in several types of cancers, including breast cancer. In the present...
13.
Ruiter D, Ferrier C, van Muijen G, Henzen-Logmans S, Kennedy S, Kramer M, et al.
Eur J Cancer
. 1998 Dec;
34(9):1334-40.
PMID: 9849413
The plasminogen activation (PA) system is involved in the breakdown and remodelling of the extracellular matrix. In the case of cancer, this is a prerequisite for invasion and metastasis. The...
14.
Sweep C, Geurts-Moespot J, Grebenschikov N, de Witte J, Heuvel J, Schmitt M, et al.
Br J Cancer
. 1998 Dec;
78(11):1434-41.
PMID: 9836475
High levels of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in breast cancer tissue extracts have been associated with rapid disease progression. In these studies, different...
15.
Schott D, Dempfle C, Beck P, Liermann A, Goldner M, Mehlem P, et al.
N Engl J Med
. 1998 Dec;
339(23):1679-86.
PMID: 9834305
No abstract available.
16.
Kennedy S, Duffy M, Duggan C, Barnes C, Rafferty R, Kramer M
Br J Cancer
. 1998 Jul;
77(10):1638-41.
PMID: 9635840
Urokinase plasminogen activator (uPA) is a serine protease involved in cancer invasion and metastasis. uPA acts in vivo by binding to a membrane receptor known as uPAR. In this study,...
17.
Autoantibodies to polymorphonuclear neutrophil elastase do not inhibit but enhance elastase activity
Morcos M, Zimmermann F, Radsak M, Worner I, Kramer M, Roland J, et al.
Am J Kidney Dis
. 1998 Jun;
31(6):978-85.
PMID: 9631842
Polymorphonuclear neutrophils (PMNs) of patients with active Wegener's granulomatosis and PMN activated in vitro express elastase on their surface as detected by autoantibodies derived from patients with ANCA-positive vasculitis or...
18.
Ferrier C, van Geloof W, de Witte H, Kramer M, Ruiter D, van Muijen G
J Histochem Cytochem
. 1998 May;
46(4):469-76.
PMID: 9524192
We present a systematic analysis of the sensitivity and specificity of immunohistochemical stainings for components of the plasminogen activation system, i.e., uPA, tPA, PAI-1, PAI-2, and uPAR, on routinely processed...
19.
Bechtel M, Wysocki N, Heidtmann A, Stark H, Fusenig N, Kramer M, et al.
Br J Dermatol
. 1998 Apr;
138(1):22-8.
PMID: 9536219
Plasminogen activation is observed in the human epidermis during re-epithelialization of epidermal defects. The activation reaction depends on plasminogen activators (PAs) associated with re-epithelializing keratinocytes. PA inhibitor type 2 (PAI-2)...
20.
Schaefer B, Lorenz C, Back W, Moll R, Sun T, Schober C, et al.
J Urol
. 1997 Dec;
159(1):284-90.
PMID: 9400496
Purpose: Our study established a technique for in vitro expansion and subsequent transplantation of autologous urothelial cells into vascularized seromuscular segments from stomach and colon in sheep. The proof of...